{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T23:52:48Z","timestamp":1785887568041,"version":"3.56.0"},"reference-count":121,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82473089"],"award-info":[{"award-number":["82473089"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.bbadis.2026.168333","type":"journal-article","created":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T15:19:07Z","timestamp":1782314347000},"page":"168333","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Immunoediting characteristics and immunotherapy strategy optimization in HBV-related hepatocellular carcinoma"],"prefix":"10.1016","volume":"1872","author":[{"given":"Junchao","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiling","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengtao","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbadis.2026.168333_bb0005","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1002\/hep.32740","article-title":"The liver cancer immune microenvironment: therapeutic implications for hepatocellular carcinoma","volume":"77","author":"Donne","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.bbadis.2026.168333_bb0010","doi-asserted-by":"crossref","first-page":"3823","DOI":"10.1038\/sj.onc.1209559","article-title":"Hepatitis B virus-related hepatocellular carcinoma: paradigms for viral-related human carcinogenesis","volume":"25","author":"Kremsdorf","year":"2006","journal-title":"Oncogene"},{"key":"10.1016\/j.bbadis.2026.168333_bb0015","doi-asserted-by":"crossref","DOI":"10.1002\/mco2.70121","article-title":"The malignant transformation of viral hepatitis to hepatocellular carcinoma: mechanisms and interventions","volume":"6","author":"Yuan","year":"2025","journal-title":"MedComm"},{"key":"10.1016\/j.bbadis.2026.168333_bb0020","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1016\/j.jhep.2022.08.021","article-title":"Global burden of primary liver cancer in 2020 and predictions to 2040","volume":"77","author":"Rumgay","year":"2022","journal-title":"J. Hepatol."},{"key":"10.1016\/j.bbadis.2026.168333_bb0025","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1038\/s41571-023-00825-3","article-title":"Global trends in hepatocellular carcinoma epidemiology: implications for screening, prevention and therapy","volume":"20","author":"Singal","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.bbadis.2026.168333_bb0030","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1038\/s41575-023-00760-9","article-title":"Global burden of hepatitis B virus: current status, missed opportunities and a call for action","volume":"20","author":"Hsu","year":"2023","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.bbadis.2026.168333_bb0035","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.00849","article-title":"Pathogenetic mechanisms of T cell dysfunction in chronic HBV infection and related therapeutic approaches","volume":"11","author":"Fisicaro","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bbadis.2026.168333_bb0040","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1172\/JCI31405","article-title":"Immune surveillance of tumors","volume":"117","author":"Swann","year":"2007","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bbadis.2026.168333_bb0045","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.02048","article-title":"HBV-induced immune imbalance in the development of HCC","volume":"10","author":"Chen","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bbadis.2026.168333_bb0050","doi-asserted-by":"crossref","first-page":"9789","DOI":"10.3390\/curroncol30110711","article-title":"Advances in immunotherapy for hepatocellular carcinoma (HCC)","volume":"30","author":"Bicer","year":"2023","journal-title":"Curr. Oncol."},{"key":"10.1016\/j.bbadis.2026.168333_bb0055","article-title":"Immune checkpoint inhibitors in HBV-caused hepatocellular carcinoma therapy","volume":"11","author":"Zhang","year":"2023","journal-title":"Vaccines"},{"key":"10.1016\/j.bbadis.2026.168333_bb0060","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbadis.2026.168333_bb0065","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s13045-024-01549-2","article-title":"Immunosuppressive tumor microenvironment and immunotherapy of hepatocellular carcinoma: current status and prospectives","volume":"17","author":"Shen","year":"2024","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.bbadis.2026.168333_bb0070","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1480520","article-title":"The load of hepatitis B virus reduces the immune checkpoint inhibitors efficiency in hepatocellular carcinoma patients","volume":"15","author":"Ji","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bbadis.2026.168333_bb0075","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1038\/ni1102-991","article-title":"Cancer immunoediting: from immunosurveillance to tumor escape","volume":"3","author":"Dunn","year":"2002","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.bbadis.2026.168333_bb0080","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/s41577-024-01111-8","article-title":"Cancer immune evasion, immunoediting and intratumour heterogeneity","volume":"25","author":"Roerden","year":"2025","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.bbadis.2026.168333_bb0085","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/s41571-018-0142-8","article-title":"Cancer immunoediting and resistance to T cell-based immunotherapy","volume":"16","author":"O\u2019Donnell","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.bbadis.2026.168333_bb0090","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1126\/science.1203486","article-title":"Cancer immunoediting: integrating immunity\u2019s roles in cancer suppression and promotion","volume":"331","author":"Schreiber","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.bbadis.2026.168333_bb0095","doi-asserted-by":"crossref","first-page":"3917","DOI":"10.1158\/1078-0432.CCR-21-1804","article-title":"Cancer immunoediting in the era of immuno-oncology","volume":"28","author":"Gubin","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbadis.2026.168333_bb0100","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12040952","article-title":"Natural killer cells: tumor surveillance and signaling","volume":"12","author":"Meza Guzman","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.bbadis.2026.168333_bb0105","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.trecan.2020.12.005","article-title":"Implications of tumor-immune coevolution on cancer evasion and optimized immunotherapy","volume":"7","author":"George","year":"2021","journal-title":"Trends Cancer"},{"key":"10.1016\/j.bbadis.2026.168333_bb0110","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1038\/s41571-022-00689-z","article-title":"Clinical implications of T cell exhaustion for cancer immunotherapy","volume":"19","author":"Chow","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.bbadis.2026.168333_bb0115","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s13045-023-01430-8","article-title":"Novel strategies for cancer immunotherapy: counter-immunoediting therapy","volume":"16","author":"Liu","year":"2023","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.bbadis.2026.168333_bb0120","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41423-019-0306-1","article-title":"Myeloid immunosuppression and immune checkpoints in the tumor microenvironment","volume":"17","author":"Nakamura","year":"2020","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.bbadis.2026.168333_bb0125","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s12943-024-02208-3","article-title":"Myeloid-derived suppressor cells (MDSCs) in the tumor microenvironment and their targeting in cancer therapy","volume":"24","author":"He","year":"2025","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.bbadis.2026.168333_bb0130","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13020210","article-title":"The functional crosstalk between myeloid-derived suppressor cells and regulatory T cells within the immunosuppressive tumor microenvironment","volume":"13","author":"Haist","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.bbadis.2026.168333_bb0135","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22115497","article-title":"Immunopathology of chronic hepatitis B infection: role of innate and adaptive immune response in disease progression","volume":"22","author":"Khanam","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbadis.2026.168333_bb0140","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2023.1206720","article-title":"Immune response and treatment targets of chronic hepatitis B virus infection: innate and adaptive immunity","volume":"13","author":"Zheng","year":"2023","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"10.1016\/j.bbadis.2026.168333_bb0145","article-title":"Hepatitis B virus persistence and reactivation","volume":"370","author":"Shi","year":"2020","journal-title":"BMJ"},{"key":"10.1016\/j.bbadis.2026.168333_bb0150","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/s41577-021-00549-4","article-title":"Immunobiology and pathogenesis of hepatitis B virus infection","volume":"22","author":"Iannacone","year":"2022","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.bbadis.2026.168333_bb0155","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1002\/hep.29479","article-title":"Epigenetic regulation of hepatitis B virus covalently closed circular DNA: implications for epigenetic therapy against chronic hepatitis B","volume":"66","author":"Hong","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.bbadis.2026.168333_bb0160","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s00281-020-00780-6","article-title":"Epigenetic modulation in chronic hepatitis B virus infection","volume":"42","author":"Dandri","year":"2020","journal-title":"Semin. Immunopathol."},{"key":"10.1016\/j.bbadis.2026.168333_bb0165","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1158\/0008-5472.CAN-22-3169","article-title":"HBx-Induced HSPA8 stimulates HBV replication and suppresses ferroptosis to support liver cancer progression","volume":"83","author":"Wang","year":"2023","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbadis.2026.168333_bb0170","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1136\/gutjnl-2023-330414","article-title":"HBV integrations reshaping genomic structures promote hepatocellular carcinoma","volume":"73","author":"Qian","year":"2024","journal-title":"Gut"},{"key":"10.1016\/j.bbadis.2026.168333_bb0175","article-title":"HBV-induced carcinogenesis: mechanisms, correlation with viral suppression, and implications for treatment","volume":"45","author":"Tu","year":"2024","journal-title":"Liver Int."},{"key":"10.1016\/j.bbadis.2026.168333_bb0180","doi-asserted-by":"crossref","DOI":"10.1186\/s40364-024-00611-y","article-title":"The impact of integrated hepatitis B virus DNA on oncogenesis and antiviral therapy","volume":"12","author":"Zhang","year":"2024","journal-title":"Biomark. Res."},{"key":"10.1016\/j.bbadis.2026.168333_bb0185","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1016\/j.jcmgh.2023.01.001","article-title":"Hepatitis B virus DNA integration drives carcinogenesis and provides a new biomarker for HBV-related HCC","volume":"15","author":"Yeh","year":"2023","journal-title":"Cell. Mol. Gastroenterol. Hepatol."},{"key":"10.1016\/j.bbadis.2026.168333_bb0190","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1002\/hep.31230","article-title":"Cell-free virus-host chimera DNA from hepatitis B virus integration sites as a circulating biomarker of hepatocellular cancer","volume":"72","author":"Li","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.bbadis.2026.168333_bb0195","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.virs.2024.06.003","article-title":"Detection of HBV DNA integration in plasma cell-free DNA of different HBV diseases utilizing DNA capture strategy","volume":"39","author":"Yang","year":"2024","journal-title":"Virol. Sin."},{"key":"10.1016\/j.bbadis.2026.168333_bb0200","doi-asserted-by":"crossref","first-page":"3772","DOI":"10.1158\/1078-0432.CCR-21-0002","article-title":"The landscape of cell-free hbv integrations and mutations in cirrhosis and hepatocellular carcinoma patients","volume":"27","author":"Zheng","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbadis.2026.168333_bb0205","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1053\/j.gastro.2019.01.251","article-title":"Use of expression profiles of HBV-DNA integrated into genomes of hepatocellular carcinoma cells to select T cells for immunotherapy","volume":"156","author":"Tan","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bbadis.2026.168333_bb0210","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1002\/hep.30317","article-title":"Natural killer cell\u2013derived interferon-gamma promotes hepatocellular carcinoma through the epithelial cell adhesion molecule\u2013epithelial-to-mesenchymal transition axis in hepatitis B virus transgenic mice","volume":"69","author":"Chen","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.bbadis.2026.168333_bb0215","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1136\/gutjnl-2023-331396","article-title":"TLR8 agonist selgantolimod regulates Kupffer cell differentiation status and impairs HBV entry into hepatocytes via an IL-6-dependent mechanism","volume":"73","author":"Roca Suarez","year":"2024","journal-title":"Gut"},{"key":"10.1016\/j.bbadis.2026.168333_bb0220","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1038\/s41586-024-07630-7","article-title":"A liver immune rheostat regulates CD8 T cell immunity in chronic HBV infection","volume":"631","author":"Bosch","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.bbadis.2026.168333_bb0225","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1136\/gutjnl-2020-322404","article-title":"TOX defines the degree of CD8+ T cell dysfunction in distinct phases of chronic HBV infection","volume":"70","author":"Heim","year":"2020","journal-title":"Gut"},{"key":"10.1016\/j.bbadis.2026.168333_bb0230","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1002\/hep.32210","article-title":"Programmed death 1 expressing CD8+CXCR5+ follicular T cells constitute effector rather than exhaustive phenotype in patients with chronic hepatitis B","volume":"75","author":"Khanam","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.bbadis.2026.168333_bb0235","doi-asserted-by":"crossref","DOI":"10.1128\/mbio.03068-23","article-title":"Stat3 activation-triggered transcriptional networks govern the early stage of HBV-induced hepatic inflammation","volume":"15","author":"Tang","year":"2024","journal-title":"mBio"},{"key":"10.1016\/j.bbadis.2026.168333_bb0240","doi-asserted-by":"crossref","DOI":"10.3390\/cells10051114","article-title":"CD4(+) T cells in chronic hepatitis B and T cell-directed immunotherapy","volume":"10","author":"Buschow","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.bbadis.2026.168333_bb0245","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1053\/j.gastro.2018.03.021","article-title":"Dysregulated response of follicular helper T cells to hepatitis B surface antigen promotes HBV persistence in mice and associates with outcomes of patients","volume":"154","author":"Wang","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bbadis.2026.168333_bb0250","doi-asserted-by":"crossref","first-page":"12410","DOI":"10.1073\/pnas.1905675116","article-title":"TOX and TOX2 transcription factors cooperate with NR4A transcription factors to impose CD8(+) T cell exhaustion","volume":"116","author":"Seo","year":"2019","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bbadis.2026.168333_bb0255","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1038\/s41586-019-0985-x","article-title":"NR4A transcription factors limit CAR T cell function in solid tumours","volume":"567","author":"Chen","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.bbadis.2026.168333_bb0260","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1136\/gutjnl-2013-306228","article-title":"Integration of tumour and viral genomic characterisations in HBV-related hepatocellular carcinomas","volume":"64","author":"Amaddeo","year":"2015","journal-title":"Gut"},{"key":"10.1016\/j.bbadis.2026.168333_bb0265","doi-asserted-by":"crossref","DOI":"10.1186\/s12967-024-05069-y","article-title":"HBV DNA polymerase upregulates the transcription of PD-L1 and suppresses T cell activity in hepatocellular carcinoma","volume":"22","author":"Jia","year":"2024","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.bbadis.2026.168333_bb0270","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1136\/gutjnl-2018-316510","article-title":"Multidimensional analyses reveal distinct immune microenvironment in hepatitis B virus-related hepatocellular carcinoma","volume":"68","author":"Lim","year":"2019","journal-title":"Gut"},{"key":"10.1016\/j.bbadis.2026.168333_bb0275","doi-asserted-by":"crossref","DOI":"10.1038\/s41421-020-00214-5","article-title":"Global immune characterization of HBV\/HCV-related hepatocellular carcinoma identifies macrophage and T-cell subsets associated with disease progression","volume":"6","author":"Song","year":"2020","journal-title":"Cell Discov."},{"key":"10.1016\/j.bbadis.2026.168333_bb0280","doi-asserted-by":"crossref","DOI":"10.1097\/HC9.0000000000000364","article-title":"Single-cell landscape identifies the immunophenotypes and microenvironments of HBV-positive and HBV-negative liver cancer","volume":"8","author":"Zheng","year":"2024","journal-title":"Hepatol. Commun."},{"key":"10.1016\/j.bbadis.2026.168333_bb0285","article-title":"Identification of CD8+ T-cell exhaustion signatures for prognosis in HBV-related hepatocellular carcinoma patients by integrated analysis of single-cell and bulk RNA-sequencing","volume":"24","author":"Li","year":"2024","journal-title":"BMC Cancer"},{"key":"10.1016\/j.bbadis.2026.168333_bb0290","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1137025","article-title":"T-cell exhaustion signatures characterize the immune landscape and predict HCC prognosis via integrating single-cell RNA-seq and bulk RNA-sequencing","volume":"14","author":"Chi","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bbadis.2026.168333_bb0295","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1016\/j.jhep.2023.08.024","article-title":"Immunosuppressive CD10+ALPL+ neutrophils promote resistance to anti-PD-1 therapy in HCC by mediating irreversible exhaustion of T cells","volume":"79","author":"Meng","year":"2023","journal-title":"J. Hepatol."},{"key":"10.1016\/j.bbadis.2026.168333_bb0300","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1111\/imm.13738","article-title":"The dual role of regulatory T cells in hepatitis B virus infection and related hepatocellular carcinoma","volume":"171","author":"He","year":"2023","journal-title":"Immunology"},{"key":"10.1016\/j.bbadis.2026.168333_bb0305","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2015.42","article-title":"T-cell exhaustion in chronic hepatitis B infection: current knowledge and clinical significance","volume":"6","author":"Ye","year":"2015","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.bbadis.2026.168333_bb0310","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1472430","article-title":"Tumor-associated macrophages and CD8+ T cells: dual players in the pathogenesis of HBV-related HCC","volume":"15","author":"Khan","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bbadis.2026.168333_bb0315","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/j.jhep.2023.01.011","article-title":"Identification of a tumour immune barrier in the HCC microenvironment that determines the efficacy of immunotherapy","volume":"78","author":"Liu","year":"2023","journal-title":"J. Hepatol."},{"key":"10.1016\/j.bbadis.2026.168333_bb0320","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1320414","article-title":"Single-cell landscape of immune cells during the progression from HBV infection to HBV cirrhosis and HBV-associated hepatocellular carcinoma","volume":"14","author":"Bai","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bbadis.2026.168333_bb0325","article-title":"The hijacking of HBV by small extracellular vesicles inhibits M1 macrophages to facilitate immune evasion","volume":"14","author":"Zhang","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bbadis.2026.168333_bb0330","doi-asserted-by":"crossref","first-page":"892","DOI":"10.7150\/thno.87962","article-title":"Reciprocal interactions between malignant cells and macrophages enhance cancer stemness and M2 polarization in HBV-associated hepatocellular carcinoma","volume":"14","author":"Zhang","year":"2024","journal-title":"Theranostics"},{"key":"10.1016\/j.bbadis.2026.168333_bb0335","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000301","article-title":"EpCAM-high liver cancer stem cells resist natural killer cell-mediated cytotoxicity by upregulating CEACAM1","volume":"8","author":"Park","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.bbadis.2026.168333_bb0340","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1111\/j.1365-2567.2008.02896.x","article-title":"Hepatitis B virus surface antigen impairs myeloid dendritic cell function: a possible immune escape mechanism of hepatitis B virus","volume":"126","author":"Op den Brouw","year":"2009","journal-title":"Immunology"},{"key":"10.1016\/j.bbadis.2026.168333_bb0345","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1136\/gutjnl-2022-328428","article-title":"Distinct single-cell immune ecosystems distinguish true and de novo HBV-related hepatocellular carcinoma recurrences","volume":"72","author":"Chen","year":"2023","journal-title":"Gut"},{"key":"10.1016\/j.bbadis.2026.168333_bb0350","doi-asserted-by":"crossref","first-page":"3686","DOI":"10.1016\/j.cell.2023.07.026","article-title":"Tumor-associated macrophages trigger MAIT cell dysfunction at the HCC invasive margin","volume":"186","author":"Ruf","year":"2023","journal-title":"Cell"},{"key":"10.1016\/j.bbadis.2026.168333_bb0355","article-title":"O-GlcNAcylation of YTHDF2 promotes HBV-related hepatocellular carcinoma progression in an N6-methyladenosine-dependent manner","volume":"8","author":"Yang","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.bbadis.2026.168333_bb0360","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1136\/gutjnl-2023-330644","article-title":"Quantification of circulating HBV RNA expressed from intrahepatic cccDNA in untreated and NUC treated patients with chronic hepatitis B","volume":"73","author":"Testoni","year":"2024","journal-title":"Gut"},{"key":"10.1016\/j.bbadis.2026.168333_bb0365","doi-asserted-by":"crossref","first-page":"559","DOI":"10.2147\/OTT.S512838","article-title":"Based on soluble immune checkpoints constructing a random survival forest model to predict the prognosis of hepatitis B virus-associated hepatocellular carcinoma","volume":"18","author":"Cai","year":"2025","journal-title":"Onco. Targets. Ther."},{"key":"10.1016\/j.bbadis.2026.168333_bb0370","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1007\/s00262-021-03103-2","article-title":"Prognostic value of soluble programmed cell death-1 (sPD-1) and soluble programmed cell death ligand-1 (sPD-L1) for hepatocellular carcinoma: a systematic review and meta-analysis","volume":"71","author":"Xue","year":"2022","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.bbadis.2026.168333_bb0375","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s00262-018-2271-4","article-title":"The correlation and prognostic value of serum levels of soluble programmed death protein 1 (sPD-1) and soluble programmed death-ligand 1 (sPD-L1) in patients with hepatocellular carcinoma","volume":"68","author":"Chang","year":"2019","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.bbadis.2026.168333_bb0380","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1186\/s40425-018-0449-0","article-title":"Soluble immune checkpoints in cancer: production, function and biological significance","volume":"6","author":"Gu","year":"2018","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.bbadis.2026.168333_bb0385","doi-asserted-by":"crossref","first-page":"318","DOI":"10.7150\/ijms.80503","article-title":"S100A11 promotes metastasis via AKT and ERK signaling pathways and has a diagnostic role in hepatocellular carcinoma","volume":"20","author":"Zheng","year":"2023","journal-title":"Int. J. Med. Sci."},{"key":"10.1016\/j.bbadis.2026.168333_bb0390","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-83145-5","article-title":"Expression and relationship of PD-L1, CD24, and CD47 in hepatitis B virus associated hepatocellular carcinoma","volume":"14","author":"Lin","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bbadis.2026.168333_bb0395","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1038\/s41575-022-00649-z","article-title":"A roadmap for serum biomarkers for hepatitis B virus: current status and future outlook","volume":"19","author":"Kramvis","year":"2022","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.bbadis.2026.168333_bb0400","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.cgh.2022.01.047","article-title":"The performance of AFP, AFP-3, DCP as biomarkers for detection of hepatocellular carcinoma (HCC): a phase 3 biomarker study in the United States","volume":"21","author":"Tayob","year":"2023","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.bbadis.2026.168333_bb0405","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2023.112960","article-title":"DNA methylation markers in the detection of hepatocellular carcinoma","volume":"191","author":"Fu","year":"2023","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.bbadis.2026.168333_bb0410","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2100070","article-title":"Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma","volume":"1","author":"Abou-Alfa","year":"2022","journal-title":"NEJM Evid."},{"key":"10.1016\/j.bbadis.2026.168333_bb0415","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/s41571-021-00573-2","article-title":"Immunotherapies for hepatocellular carcinoma","volume":"19","author":"Llovet","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.bbadis.2026.168333_bb0420","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.jhep.2021.11.030","article-title":"Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma","volume":"76","author":"Cheng","year":"2022","journal-title":"J. Hepatol."},{"key":"10.1016\/j.bbadis.2026.168333_bb0425","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/S0140-6736(23)00961-3","article-title":"Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study","volume":"402","author":"Qin","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.bbadis.2026.168333_bb0430","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.jhep.2021.08.029","article-title":"Intratumoral stem-like CCR4+ regulatory T cells orchestrate the immunosuppressive microenvironment in HCC associated with hepatitis B","volume":"76","author":"Gao","year":"2022","journal-title":"J. Hepatol."},{"key":"10.1016\/j.bbadis.2026.168333_bb0435","first-page":"63","article-title":"Real-world use of immunotherapy for hepatocellular carcinoma","volume":"14","author":"Sara","year":"2023","journal-title":"Pragmat. Obs. Res."},{"key":"10.1016\/j.bbadis.2026.168333_bb0440","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1159\/000534446","article-title":"Hepatocellular carcinoma patients with hepatitis B virus infection exhibited favorable survival from immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"13","author":"Du","year":"2024","journal-title":"Liver Cancer"},{"key":"10.1016\/j.bbadis.2026.168333_bb0445","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/s41586-021-03362-0","article-title":"NASH limits anti-tumour surveillance in immunotherapy-treated HCC","volume":"592","author":"Pfister","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.bbadis.2026.168333_bb0450","first-page":"386","article-title":"Molecular pathogenesis and systemic therapies for hepatocellular carcinoma","volume":"3","author":"Llovet","year":"2022","journal-title":"Nat. Can."},{"key":"10.1016\/j.bbadis.2026.168333_bb0455","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1097\/HEP.0000000000000237","article-title":"Mechanisms of drug resistance in HCC","volume":"79","author":"Ladd","year":"2024","journal-title":"Hepatology"},{"key":"10.1016\/j.bbadis.2026.168333_bb0460","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16203458","article-title":"Comparing lenvatinib\/pembrolizumab with atezolizumab\/bevacizumab in unresectable hepatocellular carcinoma: a real-world experience with propensity score matching analysis","volume":"16","author":"Hsu","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.bbadis.2026.168333_bb0465","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-004656","article-title":"Efficacy and safety of camrelizumab plus apatinib during the perioperative period in resectable hepatocellular carcinoma: a single-arm, open label, phase II clinical trial","volume":"10","author":"Xia","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.bbadis.2026.168333_bb0470","doi-asserted-by":"crossref","first-page":"8669","DOI":"10.1007\/s00330-023-09754-2","article-title":"Real-world efficacy and safety of TACE plus camrelizumab and apatinib in patients with HCC (CHANCE2211): a propensity score matching study","volume":"33","author":"Jin","year":"2023","journal-title":"Eur. Radiol."},{"key":"10.1016\/j.bbadis.2026.168333_bb0475","doi-asserted-by":"crossref","first-page":"e16219","DOI":"10.1200\/JCO.2025.43.16_suppl.e16219","article-title":"The efficacy and safety of donafenib combined with anti-PD-1 antibody plus transarterial chemoembolization (TACE) as first-line treatment for patients (pts) with hepatocellular carcinoma (HCC): a retrospective study","volume":"43","author":"You","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbadis.2026.168333_bb0480","doi-asserted-by":"crossref","first-page":"e16107","DOI":"10.1200\/JCO.2023.41.16_suppl.e16107","article-title":"Donafenib combined with anti-PD-1 antibody and transarterial chemoembolization (TACE) as first-line (1L) treatment for unresectable\/advanced hepatocellular carcinoma (HCC)","volume":"41","author":"Zhou","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbadis.2026.168333_bb0485","article-title":"Neoadjuvant tislelizumab plus stereotactic body radiotherapy and adjuvant tislelizumab in early-stage resectable hepatocellular carcinoma: the Notable-HCC phase 1b trial","volume":"15","author":"Li","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbadis.2026.168333_bb0490","first-page":"e16229","article-title":"Cryoablation combined with camrelizumab and apatinib in advanced hepatocellular carcinoma: a prospective, single-arm, phase II study","volume":"43","author":"Gao","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbadis.2026.168333_bb0495","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.2147\/CMAR.S547885","article-title":"Durable control of multi-refractory HBV-HCC with bevacizumab\/sintilimab\/lenvatinib triplet therapy","volume":"17","author":"Wang","year":"2025","journal-title":"Cancer Manag. Res."},{"key":"10.1016\/j.bbadis.2026.168333_bb0500","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1200\/JCO.2025.43.4_suppl.605","volume":"43","author":"Li","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbadis.2026.168333_bb0505","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1038\/s41416-025-02978-7","article-title":"Prompt initiation of durvalumab and tremelimumab for unresectable hepatocellular carcinoma in patients with chronic active hepatitis B: a phase 2 clinical trial","volume":"132","author":"Shao","year":"2025","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.bbadis.2026.168333_bb0510","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2025.1598193","article-title":"Postoperative hepatitis B virus reactivation and its impact on survival in HBV-related hepatocellular carcinoma patients undergoing conversion therapy with interventional therapy combined with tyrosine kinase inhibitors and immune checkpoint inhibitors","volume":"15","author":"Xu","year":"2025","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"10.1016\/j.bbadis.2026.168333_bb0515","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2023.1179689","article-title":"HBV reactivation and its effect on survival in HBV-related hepatocarcinoma patients undergoing transarterial chemoembolization combined with tyrosine kinase inhibitors plus immune checkpoint inhibitors","volume":"13","author":"Shen","year":"2023","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"10.1016\/j.bbadis.2026.168333_bb0520","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1516524","article-title":"Antiviral therapy can effectively suppress irAEs in HBV positive hepatocellular carcinoma treated with ICIs: validation based on multi machine learning","volume":"15","author":"Pan","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bbadis.2026.168333_bb0525","article-title":"Tumor microenvironment-mediated immune evasion in hepatocellular carcinoma","volume":"14","author":"Chen","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bbadis.2026.168333_bb0530","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1158\/0008-5472.CAN-23-3106","article-title":"Repolarization of immunosuppressive macrophages by targeting SLAMF7-regulated CCL2 signaling sensitizes hepatocellular carcinoma to immunotherapy","volume":"84","author":"Weng","year":"2024","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbadis.2026.168333_bb0535","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1097\/HEP.0000000000001202","article-title":"Enhancing HBV-specific T cell responses through a combination of epigenetic modulation and immune checkpoint inhibition","volume":"82","author":"Urbanek-Quaing","year":"2025","journal-title":"Hepatology"},{"key":"10.1016\/j.bbadis.2026.168333_bb0540","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1002\/hep.32331","article-title":"Diverse facets of MDSC in different phases of chronic HBV infection: impact on HBV-specific T-cell response and homing","volume":"76","author":"Pal","year":"2022","journal-title":"Hepatology"},{"key":"10.1016\/j.bbadis.2026.168333_bb0545","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24087463","article-title":"Metabolic reprogramming of HCC: a new microenvironment for immune responses","volume":"24","author":"Foglia","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbadis.2026.168333_bb0550","doi-asserted-by":"crossref","DOI":"10.1186\/s12967-023-04716-0","article-title":"Macrophage metabolism, phenotype, function, and therapy in hepatocellular carcinoma (HCC)","volume":"21","author":"Huang","year":"2023","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.bbadis.2026.168333_bb0555","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202301928","article-title":"PGAM1 inhibition promotes HCC ferroptosis and synergizes with anti-PD-1 immunotherapy","volume":"10","author":"Zheng","year":"2023","journal-title":"Adv. Sci."},{"key":"10.1016\/j.bbadis.2026.168333_bb0560","article-title":"HBV enhances sorafenib resistance in hepatocellular carcinoma by reducing ferroptosis via SRSF2-mediated abnormal PCLAF splicing","volume":"24","author":"Liu","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbadis.2026.168333_bb0565","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/j.jhep.2024.06.027","article-title":"Phase Ib\/IIa randomized study of heterologous ChAdOx1-HBV\/MVA-HBV therapeutic vaccination (VTP-300) as monotherapy and combined with low-dose nivolumab in virally-suppressed patients with CHB","volume":"81","author":"Tak","year":"2024","journal-title":"J. Hepatol."},{"key":"10.1016\/j.bbadis.2026.168333_bb0570","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1097\/HEP.0000000000000459","article-title":"Antiviral therapy substantially reduces HCC risk in patients with chronic hepatitis B infection in the indeterminate phase","volume":"78","author":"Huang","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.bbadis.2026.168333_bb0575","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1097\/HEP.0000000000000575","article-title":"Hepatocellular carcinoma reduced, HBsAg loss increased, and survival improved after finite therapy in hepatitis B patients with cirrhosis","volume":"79","author":"Jeng","year":"2024","journal-title":"Hepatology"},{"key":"10.1016\/j.bbadis.2026.168333_bb0580","doi-asserted-by":"crossref","first-page":"6229","DOI":"10.2147\/JIR.S471675","article-title":"Nucleos(T)ide analogue treatment has a more pronounced impact on immune repertoires of CHB patients compared to HCC patients","volume":"17","author":"Shen","year":"2024","journal-title":"J. Inflamm. Res."},{"key":"10.1016\/j.bbadis.2026.168333_bb0585","doi-asserted-by":"crossref","DOI":"10.15252\/embr.201949568","article-title":"Interferon-induced degradation of the persistent hepatitis B virus cccDNA form depends on ISG20","volume":"22","author":"Stadler","year":"2021","journal-title":"EMBO Rep."},{"key":"10.1016\/j.bbadis.2026.168333_bb0590","doi-asserted-by":"crossref","DOI":"10.3390\/v16101565","article-title":"Applications of CRISPR\/Cas as a toolbox for hepatitis B virus detection and therapeutics","volume":"16","author":"Kumar","year":"2024","journal-title":"Viruses"},{"key":"10.1016\/j.bbadis.2026.168333_bb0595","doi-asserted-by":"crossref","DOI":"10.1186\/s12951-024-02544-y","article-title":"Exosomes target HBV-host interactions to remodel the hepatic immune microenvironment","volume":"22","author":"Wu","year":"2024","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.bbadis.2026.168333_bb0600","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/S1470-2045(21)00252-7","article-title":"Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study","volume":"22","author":"Ren","year":"2021","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.bbadis.2026.168333_bb0605","doi-asserted-by":"crossref","first-page":"3698","DOI":"10.1200\/JCO.20.01757","article-title":"Hepatitis B virus screening and management for patients with cancer prior to therapy: ASCO provisional clinical opinion update","volume":"38","author":"Hwang","year":"2020","journal-title":"J. Clin. Oncol."}],"container-title":["Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0925443926001961?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0925443926001961?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T23:33:32Z","timestamp":1785886412000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0925443926001961"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":121,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S0925443926001961"],"URL":"https:\/\/doi.org\/10.1016\/j.bbadis.2026.168333","relation":{},"ISSN":["0925-4439"],"issn-type":[{"value":"0925-4439","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunoediting characteristics and immunotherapy strategy optimization in HBV-related hepatocellular carcinoma","name":"articletitle","label":"Article Title"},{"value":"Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbadis.2026.168333","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"168333"}}